Portuguese genetic testing firm CGC Genetics recently launched a Diabetes/Obesity Mutation Panel that it claims can be used for preventive purposes.
CGC Genetics, a clinical genetics testing company, recently introduced a panel for skeletal dysplasias.
The assay runs on Illumina's digital microbead-based BeadXpress system, and bolsters the Porto, Portugal-based company's menu of Array CGC tests.
The Portugal-based testing company is one of a handful of firms to adopt the holographic microbead-based platform since the US Food and Drug Administration cleared the BeadXpress earlier this year.
Exiqon's Mircury LNA MicroRNA Arrays, CGC Genetics' Prenatal Diagnostic Test
CGC Genetics' Congenital Deafness Panel, EMD Millipore's CpGenome Turbo Kit
Oxford Gene Technology's CytoSure ISCA UPD 4 x 180K Array; CGC Genetics' Microarray Panels for the Diagnosis of Bardet-Biedl Syndrome, Thrombophilia, and Warfarin Pharmacogenetics
The Portuguese genetic testing company has located its US headquarters in Newark, NJ, and it has partnered with New Jersey Medical School's Institute of Genomic Medicine.
The Portuguese lab firm received its CLIA license less than a year after being among a handful of firms to receive a warning notice from California regulators.
Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.
Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.
The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.
In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.